DDInter743 DDInter899
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Fluconazole {u} (Compound) binds {v} (Gene) CYP3A7
Fluconazole {u} (Compound) upregulates {v} (Gene) MELK
Fluconazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Fluconazole {u} (Compound) downregulates {v} (Gene) WFS1
Fluconazole {u} (Compound) causes {v} (Side Effect) Rigors
Fluconazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Ivacaftor
Fluconazole {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voriconazole
Fluconazole (Compound) binds CYP3A7 (Gene)
Fluconazole (Compound) upregulates MELK (Gene)
Fluconazole (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Fluconazole (Compound) downregulates WFS1 (Gene)
Fluconazole (Compound) causes Rigors (Side Effect)
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Fluconazole may lead to a major life threatening interaction when taken with Ivacaftor
Fluconazole (Compound) resembles Voriconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Voriconazole